Microbiota, metabolic profiles and immune biomarkers in infants receiving formula with added bovine milk fat globule membrane: a randomized, controlled trial
Frontiers in Nutrition · 04.10.2024 · 11
DOI: 10.3389/fnut.2024.1465174 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Nutrition, online erschienen am 04.10.2024. Verfasst von Chloe Christensen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Food Science and Technology, University of Nebraska-Lincoln, Lincoln, NE, United States. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mead Johnson Nutrition.
Abstract (Originalsprache)
Introduction
Few studies have evaluated the effects of milk fat globule membrane (MFGM) on microbiota and immune markers in early infant nutrition.
Methods
In this double-blind randomized study, infants (7–18 days of age) received either bovine milk-based infant formula (Control) or similar formula with an added source (5 g/L) of bovine MFGM (INV-MFGM) for 60 days. A reference group received mother’s own human milk over the same period (HM). Oral and stool samples were collected (Baseline and Day 60) to evaluate microbiota, immune markers, and metabolites.
Results
At Day 60, stool bacterial diversity and richness were higher in formula groups vs HM, as were Bifidobacterium bifidum and B. catenulatum abundance. Compared to HM, stool pH was higher in Control, while acetate, propionate, isovalerate, and total short- and branched-chain fatty acids were higher in INV-MFGM. Butyrate and lactate increased for INV-MFGM from baseline to Day 60. No group differences in oral microbiota or immune markers (α- and β-defensin, calprotectin, or sIgA) were detected, although sIgA increased over time in all study groups. Added bovine MFGM in infant formula modulated stool microbiota and short- and branched-chain fatty acids compared to human milk; changes were modest relative to control formula.
Discussion
Overall, distinct patterns of stool metabolites and microbiota development were observed based on early nutrition. Clinical trial registration ClinicalTrials.gov , identifier NCT04059666.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Food Science and Technology, University of Nebraska-Lincoln, Lincoln, NE, United States.
- Nebraska Food for Health Center, University of Nebraska, Lincoln, NE, United States.
- Complex Biosystems, University of Nebraska-Lincoln, Lincoln, Nebraska, United States.
- Medical Sciences, Reckitt/Mead Johnson Nutrition Institute, Evansville, IN, United States.
- Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, United States.
- Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, United States.
Förderung
- Mead Johnson Nutrition
Zitieren
APA
Christensen, C., Kok, C. R., Harris, C. L., Moore, N., Wampler, J. L., Zhuang, W., Wu, S. S., Hutkins, R., Izard, J., & Auchtung, J. M. (2024). Microbiota, metabolic profiles and immune biomarkers in infants receiving formula with added bovine milk fat globule membrane: a randomized, controlled trial. Frontiers in Nutrition, 11. https://doi.org/10.3389/fnut.2024.1465174
Vancouver
Christensen C, Kok CR, Harris CL, Moore N, Wampler JL, Zhuang W, et al. Microbiota, metabolic profiles and immune biomarkers in infants receiving formula with added bovine milk fat globule membrane: a randomized, controlled trial. Frontiers in Nutrition. 2024;11. doi:10.3389/fnut.2024.1465174
BibTeX
@article{Christensen2024,
author = {Christensen, Chloe and Kok, Car Reen and Harris, Cheryl L and Moore, Nancy and Wampler, Jennifer L and Zhuang, Weihong and Wu, Steven S and Hutkins, Robert and Izard, Jacques and Auchtung, Jennifer M},
title = {Microbiota, metabolic profiles and immune biomarkers in infants receiving formula with added bovine milk fat globule membrane: a randomized, controlled trial},
journal = {Frontiers in Nutrition},
year = {2024},
volume = {11},
doi = {10.3389/fnut.2024.1465174}
}
EUVIMED